Prevention of osteoporotic fractures - Should orthopedic surgeons care?

Acta Orthopaedica Scandinavica

Volumn 69, Issue 4, 1998, Pages 333-338

  Obrant, Karl J ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; ETIDRONIC ACID; FLUORIDE; VITAMIN D;

BONE MALFORMATION; BONE MASS; DIET SUPPLEMENTATION; FEMALE; HIP FRACTURE; HUMAN; ORTHOPEDIC SURGERY; OSTEOPOROSIS; PHYSICAL ACTIVITY; POSTMENOPAUSE OSTEOPOROSIS; PROTECTIVE CLOTHING; REVIEW;

EID: 0031684299     PISSN: 00016470     EISSN: None     Source Type: Journal    
DOI: 10.3109/17453679808999041     Document Type: Review

References (39)

1. Black D M, Cummings S R, Karpf D B, Cauley J A, Thompson D E, Nevitt M C et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41.
2. Cauley J A, Seeley D G, Ensrud K, Ettinger B, Black D, Cummings S R. Estrogen replacement therapy and fractures in older women. Study of osteoporotic fractures research group. Ann Int Med 1995; 122 (1): 9-16.
3. Chapuy M C, Arlot M E, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas P D, Meunier P J. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637-42.
4. Chevalley T, Rizzoli R, Nydegger V, Schlossman D, Rapin C H, Michel J P et al. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin D-replete elderly patients. Osteoporos Int 1994; 4: 245-52.
5. Chow R, Harrison J, Notarius C. Effect of two randomised exercise programs on bone mass of healthy post-menopausal women. BMJ 1987; 295: 1441-4.
6. Cooper C, Campion G, Melton L J III. Hip fractures in the elderly, a world-wide projection. Osteoporos Int 1992; 2 (6): 285-9.
7. Cummings S R, Nevitt M C, Browner W S, Stone K., Fox K M, Ensrud K E, Cauley J, Black D, Vought T M. Risk factors for hip fracture in white women. Study of osteoporotic fractures research group. N Engl J Med 1995; 332: 767-73.
8. Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S A. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990; 323: 878-83.
9. Dawson-Hughes B, Harris S, Krall E A, Dallal G E. Effect of calcium and vitamin D supplementation in on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6.
10. Ekman A, Mallmin H, Mikaëlsson K, Ljunghall S. External hip protectors to prevent osteoporotic hip fractures. Lancet 1997; 350: 563-4.
11. Fleisch, H. Bisphosphonates in bone disease. From the laboratory to the patient. Published by the Parthenon publishing group. New York 1997.
12. Harris S T, Watts N B, Jackson R D, Genant H K, Wasnich R D, Ross P, Miller P D, Licata A A, Chesnut C H III. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 5: 557-67.
13. Johnell O. Prevention of fractures in the elderly - a review. Acta Orthop Scand 1995; 66 (1): 90-8.
14. Kleerekoper M, Peterson E L, Nelson D A, Phillips E, Shork M A, Tilley B C, Parfitt A M. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1991; 1: 155-61.
15. Krölner B, Toft B, Nielsen S, Töndevold D. Physical exercise as prophylaxis against involutional vertebral bone loss - a controlled trial. Clin Sci 1983; 64: 541-6.
16. Lauritzen J B, Petersen M M, Lund B. Effect of external hip protectors on hip fractures. Lancet 1993; 341 (Jan 2): 11-3.
17. Liebermann U A, Weiss S R, Bröll J, Minne H W, Quan H, Bell N H et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43.
18. Lips P, Graafmans W C, Ooms M E, Bezemer P D, Bouter L M. Vitamin D supplementation and fracture incidence in elderly persons. A randomised placebo-controlled clinical trial. Ann Int Med 1996; 15: 124 (4): 400-6.
19. Ljunghall S, Gärdsell P, Johnell O, Larsson K, Lind E, Obrant K J, Sernbo I. Synthetic human calcitonin in postmenopausal osteoporosis. A placebo-controlled, double-blind study. Calcif Tiss Int 1991; 49: 17-9.
20. Lufkin E G, Wahner H W, O'Fallon W M, Hodgson S F, Kotowicz M A, Lane A W, Judd H L, Caplan R H, Riggs B L. Treatment of postmenopausal osteoporosis with transdermal oestrogen. Ann Int Med 1992; 117: 1-9.
21. Naessén T, Persson I, Adami H O, Bergström R, Bergkvist L. Hormone replacement therapy and the risk lor first hip fracture. A prospective, population-based cohort study. Ann Int Med 1990; 113(2): 95-103.
22. NIH. Concensus conference. Optimal calcium intake. JAMA 1994; 272: 1942-8.
23. Obrant K J, Bengnér U, Johnell O, Nilsson B, Sernbo I. Increasing age adjusted risk of fragility fractures - a sign of increasing osteoporosis by generations? Calcif Tissue Int: Invited Editorial. 1989; 44 (3): 157-67.
24. Ooms M E, Vlasman P, Lips P, Nauta J, Bouter L M, Valkenburg H A. The incidence of hip fractures in independent and institutionalised elderly people. Osteoporos Int 1994; 4: 6-10.
25. Overgaard K, Hansen M A, Jensen S B, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305: 556-61.
26. Paganini-Hill A, Chao A, Ross R K, Henderson B E. Exercise and other factors in the prevention of hip fractures: the Leisure-Word study. Epidemiology 1991; 2 (1): 16-25.
27. Pak C Y, Sakhaee K, Piziak V, Peterson R D, Breslay N A, Boyd P, Poindexter J R, Herzog J, Herd-Sakhaeee A, Haynes S. Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomised controlled trial. Ann Int Med 1994; 120 (8): 625-32.
28. Prince R L, Smith M, Dick I M, Price R I, Webb P G, Henderson N K et al. Prevention of postmenopausal osteoporosis - a comparative study of exercise, calcium supplementation and hormone replacement therapy. N Engl J Med 1991; 325: 1189-95.
29. Prince R, Divine A, Dick I, Kridl A, Kerr D, Kent N et al. The effects of calcium supplementation (milkpowder or tablets) and exercise on bone density in postmenopausal women. J Bone Min Res 1995; 10: 1068-75.
30. Reid I R, Aimes R W, Evans M C, Gamble G D, Sharp S J. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993; 328: 460-4.
31. Reid I R, Aimes R W, Evans M C, Gamle G , Sharp S J. Long-term effects of calcium supplementation on bone loss and fracture in postmenopausal women. A randomized controlled trial. Am J Med 1995; 98: 331-5.
32. Riggs B L, Hodgson S F, O'Fallon W M, Chao E Y, Wahner H W, Muhs J M, Cedel S L, Melton L J. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322 (12): 802-9.
33. Schaafsma G. The scientific basis of recommended dietary allowances for calcium. J Intern Med 1992; 231: 187-94.
34. Simkin A, Ayalon J, Leichter I. Increased trabecular bone density due to bone-loading exercise in post-menopausal osteoporotic women. Calcif Tiss Int 1987; 40: 59-63.
35. Storm T, Thamsborg G, Steiniche T, Genant H K, Sorensen O H. Effect of intermittent cyclical ethidronate therapy on bone mass and fracture rate in postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-71.
36. Tilyard M W, Spears G F S, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 326: 357-62.
37. Watts N B, Harris S T, Genant H K, Wasnich R D, Miller P D, Jackson R D, Licata A A, Ross P, Woodson G C, Yanover M J. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-9.
38. Windeler J, Lange S. Events per person-year - a dubious concept. BMJ 1995; 310 (6977): 454-6.
39. Åkesson K, Ljunghall S, Jonsson B, Sernbo I, Johnell O, Gärdsell P, Obrant K J. Assessment of biochemical markers of bone metabolism in relation to fracture in women. A population-based study. J Bone Min Res 1995; 10 (11): 1823-9.